A detailed history of Iron Triangle Partners LP transactions in Abb Vie Inc. stock. As of the latest transaction made, Iron Triangle Partners LP holds 284,657 shares of ABBV stock, worth $57.1 Million. This represents 4.97% of its overall portfolio holdings.

Number of Shares
284,657
Previous 276,098 3.1%
Holding current value
$57.1 Million
Previous $50.3 Million 2.89%
% of portfolio
4.97%
Previous 5.34%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $1.32 Million - $1.55 Million
8,559 Added 3.1%
284,657 $48.8 Million
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $4.17 Million - $4.75 Million
26,098 Added 10.44%
276,098 $50.3 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $26.7 Million - $30.9 Million
-200,000 Reduced 44.44%
250,000 $37.3 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $17.2 Million - $21.4 Million
130,000 Added 40.63%
450,000 $60.6 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $46.3 Million - $53.3 Million
320,000 New
320,000 $51 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $15.1 Million - $19.2 Million
110,000 Added 45.83%
350,000 $53.6 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $1.32 Million - $1.64 Million
-10,000 Reduced 4.0%
240,000 $38.9 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $15.4 Million - $19.4 Million
-143,024 Reduced 36.39%
250,000 $33.9 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $14.8 Million - $16.8 Million
-139,499 Reduced 26.2%
393,024 $42.4 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $24.5 Million - $27.3 Million
232,523 Added 77.51%
532,523 $60 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $30.7 Million - $33.8 Million
300,000 New
300,000 $32.5 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $355B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Iron Triangle Partners LP Portfolio

Follow Iron Triangle Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Iron Triangle Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Iron Triangle Partners LP with notifications on news.